MétaCan
Menu
Back to cohort
Record W1990707185 · doi:10.1212/wnl.0b013e31824c46be

Pentoxifylline as a rescue treatment for DMD

2012· article· en· W1990707185 on OpenAlexaff
Diana M. Escolar, Andrew Zimmerman, T. E. Bertoríni, Paula R. Clemens, Anne M. Connolly, L. Mesa, Ksenija Gorni, Andrew J. Kornberg, Hanna Kolski, Nancy L. Kuntz, Yoram Nevo, Carolina Tesi Rocha, Kanneboyina Nagaraju, Sree Rayavarapu, Lauren P. Hache, J. Mayhew, J. Florence, F. Hu, Adrienne Arrieta, Erik Henricson, Robert T. Leshner, Jean K. Mah, Masanori Igarashi, Hoda Abdel‐Hamid, Alan Pestronk, Alberto Dubroski, Monique M. Ryan, Sarah Kaminski, Marisa Bartczak, Katherine Parker, Tina Duong, Jennifer E. Thannhauser, Edit Goia, Angela W. Chiu, M. P. L. CATON, Hani Rashed, Casandra Feliciano, Judy K. Clifft, Ann Coleman, Christopher G. Bise, Kara Paulukonis, Charlie Wulf, Renee Renna, Betsy Malkus, Catherine Siener, José Corderí, Luca Capone, Marco Ferretti, D. Villano, Kate Carroll, Rachel A. Kennedy, Cam Kennedy, Lucia Chen, Wendy Korn Peterson, Krista Coleman-Wood, Brian Kotakarvi, Debbie Yaffe, Elana Weisband

Bibliographic record

VenueNeurology · 2012
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMuscle Physiology and Disorders
Canadian institutionsUniversity of AlbertaUniversity of Calgary
FundersNational Center for Advancing Translational SciencesNational Center for Research ResourcesU.S. Department of Veterans Affairs
KeywordsPentoxifyllineMedicineDouble blindRandomized controlled trialRescue therapyClinical trialSingle blindInternal medicineAlternative medicinePathologyPlacebo

Abstract

fetched live from OpenAlex

OBJECTIVE: To determine whether pentoxifylline (PTX) slows the decline of muscle strength and function in ambulatory boys with Duchenne muscular dystrophy (DMD). METHODS: This was a multicenter, randomized, double-blinded, controlled trial comparing 12 months of daily treatment with PTX or placebo in corticosteroid-treated boys with DMD using a slow-release PTX formulation (~20 mg/kg/day). The primary outcome was the change in mean total quantitative muscle testing (QMT) score. Secondary outcomes included changes in QMT subscales, manual muscle strength, pulmonary function, and timed function tests. Outcomes were compared using Student t tests and a linear mixed-effects model. Adverse events (AEs) were compared using the Fisher exact test. RESULTS: A total of 64 boys with DMD with a mean age of 9.9 ± 2.9 years were randomly assigned to PTX or placebo in 11 participating Cooperative International Neuromuscular Research Group centers. There was no significant difference between PTX and the placebo group in total QMT scores (p = 0.14) or in most of the secondary outcomes after a 12-month treatment. The use of PTX was associated with mild to moderate gastrointestinal or hematologic AEs. CONCLUSION: The addition of PTX to corticosteroid-treated boys with DMD at a moderate to late ambulatory stage of disease did not improve or halt the deterioration of muscle strength and function over a 12-month study period. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that treatment with PTX does not prevent deterioration in muscle function or strength in corticosteroid-treated boys with DMD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.290
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations25
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicMuscle Physiology and DisordersFrench-language works237,207